Aurinia Pharmaceuticals Inc.

NasdaqGM:AUPH Voorraadrapport

Marktkapitalisatie: US$1.0b

Aurinia Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

De CEO Aurinia Pharmaceuticals is Peter Greenleaf, benoemd in Apr2019, heeft een ambtstermijn van 5.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.57M, bestaande uit 7.8% salaris en 92.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.22% van de aandelen van het bedrijf, ter waarde $ 2.25M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.4 jaar en 1.3 jaar.

Belangrijke informatie

Peter Greenleaf

Algemeen directeur

US$10.6m

Totale compensatie

Percentage CEO-salaris7.8%
Dienstverband CEO5.6yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn4.4yrs
Gemiddelde ambtstermijn bestuur1.3yrs

Recente managementupdates

Recent updates

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Sep 06
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Aurinia Pharmaceuticals Appears Undervalued

Jul 05

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

May 24
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

May 05
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)

May 02

Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024

Apr 18

Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed

Mar 05

Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Feb 17
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon

Feb 15

Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential

Jan 28

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Jan 05
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Dec 18
Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Sep 14
Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Jun 11
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

May 09
Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

May 01
We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Nov 04
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus

Sep 19

Aurinia Pharmaceuticals: The Right Play Now

Aug 24

Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model

Aug 15

Analyse CEO-vergoeding

Hoe is Peter Greenleaf's beloning veranderd ten opzichte van Aurinia Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$63m

Dec 31 2023US$11mUS$823k

-US$78m

Sep 30 2023n/an/a

-US$77m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$97m

Dec 31 2022US$9mUS$791k

-US$108m

Sep 30 2022n/an/a

-US$115m

Jun 30 2022n/an/a

-US$157m

Mar 31 2022n/an/a

-US$168m

Dec 31 2021US$1mUS$724k

-US$181m

Sep 30 2021n/an/a

-US$156m

Jun 30 2021n/an/a

-US$148m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$11mUS$673k

-US$103m

Sep 30 2020n/an/a

-US$129m

Jun 30 2020n/an/a

-US$110m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$5mUS$438k

-US$88m

Compensatie versus markt: De totale vergoeding ($USD 10.57M ) Peter } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.23M ).

Compensatie versus inkomsten: De vergoeding van Peter is gestegen terwijl het bedrijf verliesgevend is.


CEO

Peter Greenleaf (54 yo)

5.6yrs

Tenure

US$10,573,359

Compensatie

Mr. Peter S. Greenleaf, M.B.A., is Director at NVN Liquidation Inc. He serves as Director at ValenzaBio, Inc. since August 2022. He has been Chief Executive Officer and Director of Aurinia Pharmaceuticals...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Peter Greenleaf
CEO & Director5.6yrsUS$10.57m0.22%
$ 2.2m
Joseph Miller
Chief Financial Officer4.6yrsUS$3.98m0.078%
$ 808.5k
Matthew Donley
Chief Operations Officerno dataUS$4.56m0.11%
$ 1.1m
Stephen Robertson
Executive Vice President of General Counsel4yrsUS$3.60m0.055%
$ 565.0k
Andrea Christopher
Head of the Corporate Communications & Investor Relationsno datageen gegevensgeen gegevens
Michael Martin
Chief Business Officer4.4yrsUS$702.00kgeen gegevens
Sue Evans
Senior Vice President of Global Regulatory Affairsno datageen gegevensgeen gegevens
Scott Habig
Chief Commercial Officer2.3yrsgeen gegevens0.071%
$ 732.0k
Gregory Keenan
Chief Medical Officerno datageen gegevensgeen gegevens
Ann Daus
Senior Vice President of Qualityno datageen gegevensgeen gegevens
Premchandran Ramiya
Senior Vice President of Manufacturing & Supply Chainno datageen gegevensgeen gegevens
DeDe Sheel
Vice President of Investor Relationno datageen gegevensgeen gegevens

4.4yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AUPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Peter Greenleaf
CEO & Director5.6yrsUS$10.57m0.22%
$ 2.2m
Kevin Tang
Chairmanless than a yeargeen gegevensgeen gegevens
Robert Foster
Director1.2yrsUS$474.21k0%
$ 0
Jill Leversage
Independent Director5yrsUS$267.28k0.010%
$ 106.1k
Jeffrey Bailey
Independent Director1.3yrsUS$361.51k0%
$ 0
Karen Smith
Independent Director1.3yrsUS$359.41k0%
$ 0
David R. Jayne
Independent Non-Executive Director9.5yrsUS$249.92k0.031%
$ 319.9k

1.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AUPH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw bestuur.